All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The AML Global Portal were delighted to speak to Brian Huntly, University of Cambridge, Cambridge, UK, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Brian Huntly: What is the impact of EZH2 mutations in AML?
He outlined the prognostic significance of EZH2 mutations for patients with AML and how they can now be targeted by novel inhibitors.
What is the impact of EZH2 mutations in AML?
Subscribe to get the best content related to AML delivered to your inbox